Lung Transplantation for Cystic Fibrosis
Joseph P. Lynch III, MD, David M. Sayah, MD, PhD, John A. Belperio, MD, S. Sam Weigt, MD. Disclosures. Semin Respir Crit Care Med. 2015;36(2):299-320. Print. Abstract and Introduction; Lung Transplantation for Cystic Fibrosis · Lung Transplantation for ...
Medscape - Tue, 19 May 2015 20:56



Don links rise in cancer, infertility, others to mycotoxins
Fapohunda said emerging and re emerging zygomycoses have now necessitated the shift toward antifungal resistance. Zygomycosis is the broadest term to refer to infections caused by bread mold fungi of the zygomycota phylum. The biotechnologist said ...
The Guardian Nigeria - Wed, 13 May 2015 17:11

Isavuconazonium sulfate: A new azole for life-threatening fungal infections
Isavuconazonium sulfate (Cresemba—Astellas) has received FDA approval to treat invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). Aspergillosis and mucormycosis are fungal infections caused by the Aspergillus species and ...
American Pharmacists Association, pharmacist.com - Fri, 01 May 2015 14:02

Astellas Launches CRESEMBA® (isavuconazonium sulfate) in the United States ...
... announced today that CRESEMBA® (isavuconazonium sulfate), the prodrug for isavuconazole, is now available in the United States for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
PR Newswire (press release) - Mon, 27 Apr 2015 07:06

CRESEMBA® (isavuconazonium sulfate) Data to be Presented at the European ...
... Drug Administration (FDA) approved a New Drug Application (NDA) for the use of CRESEMBA in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
PR Newswire (press release) - Thu, 23 Apr 2015 07:47

Astellas introduces Cresemba in US markets to treat invasive aspergillosis and ...
... of people around the world, has launched Cresemba (isavuconazonium sulfate), the prodrug for isavuconazole, in the United States for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).
pharmabiz.com - Tue, 28 Apr 2015 22:26



FDA approves Astellas' NDA for Cresemba to treat zygomycosis
The US Food and Drug Administration (FDA) has approved Astellas' New Drug Application (NDA) for the use of Cresemba (isavuconazonium sulfate) to treat aspergillosis and invasive mucormycosis (also known as zygomycosis). The prodrug for ...
Pharmaceutical Business Review - Sun, 08 Mar 2015 23:48

Astellas Cresemba Gains FDA Approval, Under Review in EU
Zacks.com - Mon, 09 Mar 2015 12:41

US approval for Astellas' new antifungal drug Cresemba
PMLiVE - Mon, 09 Mar 2015 03:30

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis ...
News-Medical.net - Sun, 08 Mar 2015 05:03

Astellas' Cresemba Gains FDA Approval, Under Review in EU - Analyst Blog
Nasdaq - Mon, 09 Mar 2015 12:41

Basilea reports U.S. FDA approval of isavuconazole for the treatment of ...
GlobeNewswire (press release) - Fri, 06 Mar 2015 14:14

Astellas introduces Cresemba in US to treat invasive aspergillosis and ...
Astellas has launched Cresemba (isavuconazonium sulfate), the prodrug for isavuconazole in the US to treat adults with invasive aspergillosis and invasive mucormycosis (zygomycosis). Both invasive aspergillosis and mucormycosis are life-threatening ...
Pharmaceutical Business Review - Tue, 28 Apr 2015 04:15


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014